Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non–Small-Cell Lung Cancer

Nuria Chic; Laura Mezquita; Mihaela Aldea; Ralph Chebib; Caroline Caramella; David Planchard; Benjamin Besse

doi:10.1016/j.cllc.2020.07.013

Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF^V600E-Mutant Metastatic Non–Small-Cell Lung Cancer

Nuria Chic, Laura Mezquita, Mihaela Aldea, Ralph Chebib, Caroline Caramella, David Planchard, Benjamin Besse

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

5 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	e54-e56
journal	Clinical Lung Cancer
Volume	22
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.cllc.2020.07.013
état	Publié - 1 janv. 2021

Accès au document

10.1016/j.cllc.2020.07.013

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{97711f79d3414096ad453b88474ded34,

title = "Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non–Small-Cell Lung Cancer",

keywords = "BRAF inhibitor, Interstitial lung disease, MEK inhibitor, NSCLC",

author = "Nuria Chic and Laura Mezquita and Mihaela Aldea and Ralph Chebib and Caroline Caramella and David Planchard and Benjamin Besse",

note = "Funding Information: L.M. reports work with Roche Diagnostics, Bristol-Myers Squibb, Tecnofarma, Roche, AstraZeneca, and Chugai, outside the submitted work. C.C. reports work with Bristol-Myers Squibb and Pfizer, outside the submitted work. D.P. reports work with AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Sanofi-Aventis, Taiho Pharma, Novocure, and Medimmun, outside the submitted work. B.B. reports grants from AbbVie , Amgen , AstraZeneca , Biogen , Blueprint Medicines , BMS , Celgene , Eli Lilly , GSK , Ignyta , Ipsen , Merck KGaA , MSD , Nektar , Onxeo , Pfizer , PharmaMar , Sanofi , Spectrum Pharmaceuticals , Takeda , and Tiziana Pharma ; and work with Nerviano, GSK, Pfizer, Roche-Genentech, Lilly, OSE Pharma, MSD, Celgene, Stemcentrx, Ignyta, AbbVie, Loxo Oncology, AstraZeneca, and Blueprint Medicines, outside the submitted work. The other authors have stated that they have no conflict of interest. Funding Information: L.M. reports work with Roche Diagnostics, Bristol-Myers Squibb, Tecnofarma, Roche, AstraZeneca, and Chugai, outside the submitted work. C.C. reports work with Bristol-Myers Squibb and Pfizer, outside the submitted work. D.P. reports work with AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Sanofi-Aventis, Taiho Pharma, Novocure, and Medimmun, outside the submitted work. B.B. reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma; and work with Nerviano, GSK, Pfizer, Roche-Genentech, Lilly, OSE Pharma, MSD, Celgene, Stemcentrx, Ignyta, AbbVie, Loxo Oncology, AstraZeneca, and Blueprint Medicines, outside the submitted work. The other authors have stated that they have no conflict of interest.",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/j.cllc.2020.07.013",

language = "English",

volume = "22",

pages = "e54--e56",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "1",

}

TY - JOUR

T1 - Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non–Small-Cell Lung Cancer

AU - Chic, Nuria

AU - Mezquita, Laura

AU - Aldea, Mihaela

AU - Chebib, Ralph

AU - Caramella, Caroline

AU - Planchard, David

AU - Besse, Benjamin

N1 - Funding Information: L.M. reports work with Roche Diagnostics, Bristol-Myers Squibb, Tecnofarma, Roche, AstraZeneca, and Chugai, outside the submitted work. C.C. reports work with Bristol-Myers Squibb and Pfizer, outside the submitted work. D.P. reports work with AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Sanofi-Aventis, Taiho Pharma, Novocure, and Medimmun, outside the submitted work. B.B. reports grants from AbbVie , Amgen , AstraZeneca , Biogen , Blueprint Medicines , BMS , Celgene , Eli Lilly , GSK , Ignyta , Ipsen , Merck KGaA , MSD , Nektar , Onxeo , Pfizer , PharmaMar , Sanofi , Spectrum Pharmaceuticals , Takeda , and Tiziana Pharma ; and work with Nerviano, GSK, Pfizer, Roche-Genentech, Lilly, OSE Pharma, MSD, Celgene, Stemcentrx, Ignyta, AbbVie, Loxo Oncology, AstraZeneca, and Blueprint Medicines, outside the submitted work. The other authors have stated that they have no conflict of interest. Funding Information: L.M. reports work with Roche Diagnostics, Bristol-Myers Squibb, Tecnofarma, Roche, AstraZeneca, and Chugai, outside the submitted work. C.C. reports work with Bristol-Myers Squibb and Pfizer, outside the submitted work. D.P. reports work with AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Sanofi-Aventis, Taiho Pharma, Novocure, and Medimmun, outside the submitted work. B.B. reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma; and work with Nerviano, GSK, Pfizer, Roche-Genentech, Lilly, OSE Pharma, MSD, Celgene, Stemcentrx, Ignyta, AbbVie, Loxo Oncology, AstraZeneca, and Blueprint Medicines, outside the submitted work. The other authors have stated that they have no conflict of interest.

PY - 2021/1/1

Y1 - 2021/1/1

KW - BRAF inhibitor

KW - Interstitial lung disease

KW - MEK inhibitor

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85090490933&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.07.013

DO - 10.1016/j.cllc.2020.07.013

M3 - Article

C2 - 32896487

AN - SCOPUS:85090490933

SN - 1525-7304

VL - 22

SP - e54-e56

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 1

ER -